A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
In October 2013, A&W opened its first new concept restaurant, A&W Burgers Chicken Floats. The new concept focuses on fresh made-to-order food and heavily emphasizes customer service. The menu features burgers made with fresh beef and a choice of toppings, hand-breaded chicken tenders, all-beef hot dogs, and several sides. The new management gave A&W a significant boost in the number of locations, with 2017 scheduled to have more openings than closures. For 2018, A&W projected an increase in its franchising operations and opening new restaurants. In April 2019, A&W returned to Singapore after a 16-year absence, its first location being at Jewel Changi Airport. In June 2019, the A&W chain started moving its headquarters to the University of Kentucky Coldstream Research Campus in 2019. A&W announced in March 2022 that it was going to withdraw from the Thai market due to economic losses. The restaurants shut down on March 20. A franchise was given to western New York in early 2023, with three locations, the first of which in Niagara Falls, set to open between May and June of that year. There are nearly 1,000 A&W Restaurants worldwide that are owned or franchised through A Great American Brand, with approximately 475 of these restaurants located in the U.S. as of October 2024. A&W rebounded its profits in the first half of 2024, emphasis on its growth is given mainly to single-brand restaurants, as well as restaurants in less conventional locations. In November 2024, the chain announced its entrance to the Milwaukee and Madison markets in Wisconsin.
== Mechanical comminution == Mechanical comminution is the dominant family of techniques for industrial micronization. The process typically begins with coarse size reduction — crushing by hammer or impact mills and cutting by blade mills — which produces feed material in the millimetre-to-coarse-micrometre range from bulk solids. Conventional tumbling ball mills, in which a rotating drum loaded with steel or ceramic grinding media reduces the feed by impact and abrasion, are widely used for grinding in the 50–500 μm range but do not typically achieve micrometre-scale particle sizes on their own. True micronization to the 1–10 μm range is achieved by higher-energy mechanical techniques, principally jet milling for dry powders and wet bead milling or high-pressure homogenization for aqueous suspensions, which are described in the following sections. Industrial pharmaceutical micronization is dominated by mechanical comminution methods, particularly air-jet milling (also called fluid energy milling) and cryogenic milling. These mechanical methods scale from gram-level development batches to multi-metric-ton commercial campaigns and operate under current good manufacturing practice (cGMP) regulations such as 21 CFR Part 211 and ICH Q7. The choice of micronization technology depends on the active pharmaceutical ingredient's physical properties. Air-jet milling produces narrow, log-normal particle-size distributions typically with D50 below 5 µm and span ≤ 2, and is the standard approach for dry powder inhalation products and poorly soluble oral solids.
The second head of the institute was Alexander Bogomolets (see further). 1930s Beginning of attempts of rejuvenation by methods of cell injections. A special role belongs here to the Swiss physician Paul Niehans – he was not the first but he was the one who developed this approach the most. Among his patients there were many famous people (including Winston Churchill, Charles de Gaulle, Pope Pius XII). So, in 1952, about 3000 injections of about 10 cm3 of cell suspension were reported. As a consequence, cell therapy and regenerative medicine were formed. Since the 1960s, attempts have been made to inject not only whole cells but also their constituent parts (such as isolated DNA and RNA). But usage of embryonic drugs sometimes caused serious complications, so the American association of physicians recognized the method of cell therapy as dangerous. 1930 The first world's journal about aging and longevity. It was established in Japan and has the name Acta Gerontologica Japonica (Yokufuen Chosa Kenkyu Kiyo). 1933 The first institute in the world dedicated to study of aging. It was created in Kishinev (at that time inside the Kingdom of Romania) by Dimu Kotsovsky. Initially the institute was maintained by his own means, and was subsequently recognized by the Romanian government. The name is Romanian: Institutul Pentru Studierea si Combaterea Batranetii = German: Institut für Altersforschung und Altersbekämpfung = Institute for The Study and Combat of Aging.
==== Offender rehabilitation ==== Traditional work with offenders has focused on their deficits (e.g., with respect to socialization, and schooling) and other "criminogenic" risk-factors. Rehabilitation more often than not has taken the form of forced treatment or training, ostensibly for the good of the offender, and the community. Arguably, this approach has shortcomings, suggesting a need to make available additional positive options to treatment staff so they can best assist offenders, and so that offenders can better find their way forward. Positive psychology has made recent inroads with the advent of the "Good Lives Model", developed by Tony Ward, Shadd Maruna, and others. With respect to rehabilitation: "Individuals take part ... because they think that such activities might either improve the quality of their life (an intrinsic goal) or at least look good to judges, parole boards and family members (an extrinsic goal)."
Sources: en.wikipedia.org
The chain-termination method developed by Frederick Sanger and coworkers in 1977 soon became the method of choice, owing to its relative ease and reliability. When invented, the chain-terminator method used fewer toxic chemicals and lower amounts of radioactivity than the Maxam and Gilbert method. Because of its comparative ease, the Sanger method was soon automated and was the method used in the first generation of DNA sequencers. Sanger sequencing is the method which prevailed from the 1980s until the mid-2000s. Over that period, great advances were made in the technique, such as fluorescent labelling, capillary electrophoresis, and general automation. These developments allowed much more efficient sequencing, leading to lower costs. The Sanger method, in mass production form, is the technology which produced the first human genome in 2001, ushering in the age of genomics. However, later in the decade, radically different approaches reached the market, bringing the cost per genome down from $100 million in 2001 to $10,000 in 2011.
==== De novo motif recognition from protein ==== In 2018, a Markov random field approach has been proposed to infer DNA motifs from DNA-binding domains of proteins. Motif Discovery Algorithms Motif discovery algorithms use diverse strategies to uncover patterns in DNA sequences. Integrating enumerative, probabilistic, and nature-inspired approaches, demonstrate their adaptability, with the use of multiple methods proving effective in enhancing identification accuracy. Enumerative Approach: Initiating the motif discovery journey, the enumerative approach witnesses algorithms meticulously generating and evaluating potential motifs. Pioneering this domain are Simple Word Enumeration techniques, such as YMF and DREME, which systematically go through the sequence in search of short motifs. Complementing these, Clustering-Based Methods such as CisFinder employ nucleotide substitution matrices for motif clustering, effectively mitigating redundancy. Concurrently, Tree-Based Methods like Weeder and FMotif exploit tree structures, and Graph Theoretic-Based Methods (e.g., WINNOWER) employ graph representations, demonstrating the richness of enumeration strategies. Probabilistic Approach: Diverging into the probabilistic realm, this approach capitalizes on probability models to discern motifs within sequences. MEME, a deterministic exemplar, employs Expectation-Maximization for optimizing Position Weight Matrices (PWMs) and unraveling conserved regions in unaligned DNA sequences.
==== Council house sales ==== Heseltine was a convert to the sale of council houses, a policy pioneered by some Conservative local authorities, e.g. Birmingham. He also favoured the policy of giving away houses, a policy first mooted from the backbenches by Peter Walker in the mid-1970s, not least as some local authorities were spending more on maintenance than they were recouping in rents. Thatcher, who was concerned at the reaction from those who had made financial sacrifices to buy their homes, was initially sceptical. After taking office Heseltine issued a circular enabling councils, if they chose, to sell houses at 30% discount and to offer 100% mortgages. The Housing Act 1980 enacting Right to Buy was delayed by a Lords amendment and did not reach the statute book until the end of 1980. Some councils were slow in processing applications (one even threatened to house "problem" families next door to those who bought) and Heseltine made an example of Norwich by setting up a DOE sales office there; Norwich council took him to court and lost. At the time Heseltine permitted councils to use up to 75% of sales receipts for renovating the housing stock, and was angry in later years when this was cut back by the Treasury. Heseltine also insisted on the doubling of rents to encourage buying. During the 1980s over a million council houses, around 20% of the stock, were sold, and by 1987 Labour had dropped their opposition to the Right to Buy.
Single-domain antibodies have been tested as a new therapeutic tool against multiple targets. In mice infected with influenza A virus subtype H5N1, nanobodies directed against hemaglutinin suppressed replication of the H5N1 virus in vivo and reduced morbidity and mortality. nanobodies targeting the cell receptor binding domain of the virulence factors toxin A and toxin B of Clostridioides difficile were shown to neutralize cytopathic effects in fibroblasts in vitro. Nanobody conjugates recognizing antigen presenting cells have been successfully used for tumor detection or targeted antigen delivery to generate strong immune response. Orally available single-domain antibodies against E. coli-induced diarrhoea in piglets have been developed and successfully tested. Other diseases of the gastrointestinal tract, such as inflammatory bowel disease and colon cancer, are also possible targets for orally available single-domain antibodies. Detergent-stable species targeting a surface protein of Malassezia furfur have been engineered for use in anti-dandruff shampoos. As an approach for photothermal therapy nanobodies binding to the HER2 antigen, which is overexpressed in breast and ovarian cancer cells, were conjugated to branched gold nanoparticles (see figure). Tumor cells were destroyed photothermally using a laser in a test environment. Caplacizumab, a single-domain antibody targeting von Willebrand factor is in clinical trials for the prevention of thrombosis in patients with acute coronary syndrome.
Horses are used to measure distances in horse racing – a horse length (shortened to merely a length when the context makes it obvious) equals roughly 8 feet or 2.4 metres. Shorter distances are measured in fractions of a horse length; also common are measurements of a full or fraction of a head, a neck, or a nose.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.